Recherche avancée

Burkhart Grund occupe le poste de Group Chief Finance Officer & Executive Director à la Compagnie Financière Richemont SA. Dans le passé, il a été directeur financier de Montblanc France SASU, directeur financier & vice-président de Van Cleef & Arpels SA et directeur financier de Procter & Gamble Deutschland GmbH. Il a obtenu un diplôme de premier cycle de la Georgia Southern University et un diplôme de premier cycle de l'Université de Mnster.

Birgit Grund worked as a Senior Vice President-Investor Relations at Fresenius SE & Co. KGaA.

Vlado Grund served as a Member-Supervisory Board at Koncar-Distributivni.
I Specijalni Transformatori dd from 2015 to 2019.

Nicholas Grund is currently the Chief Commercial Officer at Akebia Therapeutics, Inc. He previously held positions as the Head-Specialty Care at Genzyme Corp from 2007 to 2015, the Chief Commercial Officer & Executive VP at AMAG Pharmaceuticals, Inc. from 2016 to 2019, and as the President-Eurofins at Transplant Genomics, Inc. from 2021 to 2022.
Mr. Grund also worked as a Principal at Bayer Diagnostics Corp.
from 1995 to 2002.
He holds an MBA from Northeastern University and an undergraduate degree from the University of Massachusetts.

Michael Grund worked as an Associate Analyst at Moody's Investors Service, Inc. from 2017 to 2021.
Prior to that, he worked as an Analyst at National Public Finance Guarantee Corp.
Mr. Grund received an undergraduate degree from Wake Forest University.

Ines Grund is currently a Director at Thames Water Ltd., Southern Gas Networks Plc, Scotland Gas Networks Plc, Mapleco1 Ltd., SGN Midco Ltd., SGN PledgeCo Ltd., and SGN Place Ltd.
He previously worked as a Director at Scotia Gas Networks Ltd., Kemble Water Holdings Ltd., and Maple TopCo Ltd.